CDK12 and cancer: Considering the higher proportion of fHER2 IHC-negative cases carrying this mutation, it is possible that it might be associated with the amplification of additional cancer-related genes in the region (e.g.CDK12, TOP2A, EIF1, and STAT3) rather than inducing fHER2 overexpression as typically observed in HBCs.